CFTR Protein Structure

 Proposed model of 3D CFTR structure in the cell membrane.
Proposed model of 3D CFTR structure in the cell membrane.
Overview

The cystic fibrosis transmembrane conductance regulator (CFTR) is a 1480 amino acid membrane bound glycoprotein with a molecular mass of 170,000. It is a member of the ATP binding cassette (ABC) superfamily of proteins which includes several clinically important proteins such as P-glycoprotein (P-gp), multidrug resistance associated protein and the TAP transporters.
The protein is comprised of two, six span membrane bound regions each connected to a nuclear binding factor which binds ATP. Between these two units is an R-domain which is comprised of many charged amino acids. The R-domain is a unique feature of CFTR within the ABC superfamily.

 

Nuclear Binding Domains (NBD)

Many of the mutations identified in CF occur in the first nucleotide binding domain (NBD1), while very few occur in NBD2. This is a common feature of the ABC superfamily and indicates a separate role for the two binding domains. The most common mutation in CF, deltaF508 occurs in NBD1. This results in a 3 bp deletion and the loss of a phenylalanine residue. The deletion causes a protein trafficking defect. If this defect is overcome then the protein can form a functional channel. This can be brought about by over expression of CFTR or by culturing cells at > 30 oC. The NBDs contain a number of highly conserved motifs predicted to bind and hydrolyse ATP. Site directed mutagenesis at these motifs have indicated that ATP binds to both NBDs to control of the gating of the channel.

The Regulatory Domain

CFTR
2D representation of CFTR in the cell membrane.

The R domain of CFTR is encoded by exon 13 and it spans the region between NBF1 and the second transmembrane region. It contains several potential sites for phosphorylation by
cAMP-dependent PKA or PKC. The activity of CFTR as an ion channel depends upon phosphorylation of the R-domain and binding of ATP to the nuclear binding domains. The N terminal portion of the R-domain (RD1) is highly conserved between species but there is a lower degree of conservation between the rest of the domain (RD2).

Extracellular Domains

A mere 4 % of the CFTR protein is found in the extracellular loops (see the gene sequence and structure section). The loops are designated according to the membrane spanning regions they connect, M1-M2, M3-M4, M5-M6, M7-M8, M9-M10 and M11-M12 (always odd to even). With the exception of the M1-M2 and the M7-M8 these extracellular domains are very short. The M7-M8 loop contains two N-linked glycosylation sites.

Transmembrane Domains

19 % of the CFTR protein makes up the twelve transmembrane domains (M1 - M12). These domains have been shown to be comprised of typical a-helical secondary structure. Many of the residues within these regions form the channel lining residues and have a major role in the regulation of pore function. Six positively charged residues within the transmembrane domains [K95 (M1), R134 (M2), R334 (M6), K335 (M6), R347 (M6) and R1030 (M10] are well conserved across species. Two of these are associated with mutations causing CF, R334Q/W and R347C/H/L/P.

The Intracellular Domains

Sequences within the intracellular loops (ICL1 - 4) have been shown to be important for the processing of CFTR and correct delivery to the cell membrane. Site directed mutagenesis studies in ICL2 and ICL3 have indicated that these sections may be close to the intracellular opening of the CFTR pore. Changes in these regions have been shown to alter the conductance state of the channel.

Site map

 

Home
News
Contact Details
Follow us on Facebook
Events & Fundraising
Careers
Site Feedback
Site Search
The CF Trust

 

Information for Patients on Our Clinical Trial
Latest Clinical Trial News
Contact Details

 

Consortium Members' Internal Website
About Us
How the Consortium Works
Profiles of the Strategy Group
Scientific Advisory Committee
Milestones
Comminuty Review
Oxford University Gene Medicine
Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial

 

Our Research
Optimisation of pDNA
Aerosol Delivery
Viral Vectors Development
Assay Development
Core Facilities
Consortium Patents

 

Clinical Programme
GL67A/pGM169
Clinical Team
Tracking Study
The Run-in Study
Single Dose Clinical Trial
Multi Dose Clinical Trial

 

Cystic Fibrosis
What is CF?
History of CF
Discovery of the CFTR Gene
What Causes CF?
CFTR Protein Structure
Cystic Fibrosis Links
Gene Therapy
Introduction to CF Gene Therapy
Why use Gene Therapy for CF?
Other CF Gene Therapy Groups
Examples of Successful Gene Therapy
Gene Therapy Links

 

Publications
Publications in Journals
Conference Posters & Presentations
Book Chapters
Lectures

 

Medical Futures Innovation Award 2011
Introductory Video
What is a Lentivirus
Production of Lentiviruses
Progress to Date
DNAVec
Photo Gallery